This Biotech Wants to Turn Lung Medicine Into a 10-Minute Breathing Session

That's like watering your garden with a targeted drip system instead of turning on a fire hose and hoping some water reaches the flowers.

The Data So Far

Avalyn ran a Phase 1b trial called ATLAS across 25 sites in six countries, enrolling 91 IPF patients. The results look genuinely interesting.

More than 70% of patients on the higher dose (100 mg twice daily) saw their fibrosis scores stabilize or actually improve on CT imaging at week 24. That's notable for a disease that basically only gets worse over time. Patients with imaging improvements also reported the biggest quality-of-life gains, with meaningful benefits showing up as early as week eight.

The side-effect profile tells its own story. Cough occurred in about 15% of patients, and rash in roughly 12%, both significantly lower than what oral pirfenidone typically produces. Some patients in the open-label extension have now been on the drug for more than four and a half years with no new safety concerns emerging.

The whole treatment takes less than 10 minutes via a specialized nebulizer. Pop in a cartridge, breathe, get on with your day.

It's Not Just One Drug

Avalyn isn't a one-trick pony. Beyond AP01, the company is developing AP02, an inhaled version of nintedanib (the other approved oral drug for IPF). AP02 is currently in a Phase 2 trial called AURA, which started dosing patients in March 2026 and is enrolling 160 people.

Then there's AP03, a combination of both pirfenidone and nintedanib in a single inhaled dose. It's still preclinical, but the concept is compelling: two proven drugs, delivered together, straight to the target organ. If it works, it could be the equivalent of a one-two punch that oral therapy can't match without doubling the side effects.

IPO proceeds will fund AP01 through late-stage trials, AP02 through Phase 2/3, and AP03 into its first human study.

The IPO Window Is Open (For Now)

Avalyn's timing is deliberate. The biotech IPO market is having its best stretch since the 2021 boom. Six biotech companies completed IPOs in the first quarter of 2026 alone, with a median deal size of $287.5 million. That's already close to matching all of 2025, when only eight biotech IPOs priced for the entire year.

But "open window" doesn't mean "easy money." Investors in 2026 are picky. They want mature pipelines, Phase 2 or Phase 3 data, and clear regulatory paths. Early-stage companies with nothing but preclinical programs are staying private.

Avalyn fits the profile that public investors seem to want right now. It has clinical data across multiple assets, a clear unmet medical need, and a story that's easy to understand. It also helps that CEO Lyn Baranowski has been here before: she previously served as COO at Altavant Sciences (acquired for $3 billion). She's raised more than $300 million for Avalyn before even going public, including a $100 million Series D last July.

The Big Question

Phase 1b data is encouraging, but it's not proof. The ATLAS trial didn't include a placebo group; comparisons rely on historical data from oral pirfenidone trials. That's useful context, not a controlled experiment. Everything rides on the upcoming Phase 2b and Phase 3 trials, which will need to show real, placebo-controlled benefits.

The concept of inhaled delivery for lung diseases isn't revolutionary by itself. Asthma inhalers have existed for decades. But applying that logic to anti-fibrotic drugs, which were designed as oral medications, required over a decade of formulation work. Avalyn was founded in 2011, and it's taken 15 years to reach this stage.

The respiratory drug development graveyard is well-populated. Plenty of good ideas have failed in larger trials. But if AP01 delivers in Phase 3 what it hinted at in Phase 1b, Avalyn could fundamentally change the treatment experience for hundreds of thousands of pulmonary fibrosis patients worldwide.

The IPO will tell us whether public investors believe the same thing. Given the banks lined up and the current market mood, the smart bet is that this one prices. What happens after that depends on the lungs.

The CAR-T Startup Betting $110M It Can Crack Liver Cancer

A Shanghai biotech just raised $110 million to chase what nobody has achieved: a CAR-T therapy that actually works against solid tumors. Oricell Therapeutics is betting it can crack liver cancer and IPO on the other side.